Original reporting and analysis on the stories shaping biotech.
Pfizer's HYMPAVZI just got a major FDA label expansion, opening the door to kids as young as six and the hardest-to-treat hemophilia patients with inhibitors. A once-weekly shot might finally replace the IV gauntlet that's defined pediatric hemophilia care for decades.
Tango Therapeutics reported a 92% response rate in pancreatic cancer patients, a disease where second-line treatments barely crack 15%. The stock surged 53% in a single day, and Wall Street is calling the data "groundbreaking."
Sanofi's venglustat just scored FDA Priority Review for Gaucher disease type 3, and it could become the first approved therapy to actually cross the blood-brain barrier and treat the devastating neurological symptoms. The decision date is set for November 25, 2026.
Inhaled insulin flopped spectacularly with adults. Now MannKind's Afrezza just became the first needle-free mealtime insulin approved for kids, targeting a population where needle fear isn't just annoying — it's clinically dangerous.
A drug that was nearly killed by its own toxicity just posted Phase 3 results for the first-ever once-weekly oral HIV pill. Merck and Gilead's comeback story could reshape how millions of people manage the virus.
Boehringer Ingelheim's obesity drug survodutide just got its full data day at ADA 2026, and Wall Street's verdict was brutal. The drug works, but in a market dominated by Lilly and Novo, 'works' might not be enough.
Roche just dropped $700 million upfront on Nurix's BTK degrader bexobrutideg, with the total deal reaching up to $2.3 billion. It's the strongest signal yet that protein degradation has crossed from lab curiosity to pipeline priority, and it could reshape the future of blood cancer treatment.
GSK just dropped £44 million on a London biotech trying to do something most scientists thought was impossible: reverse scar tissue. The deal with Engitix is the latest piece of a fibrosis strategy that's quietly become one of pharma's biggest bets.
Eli Lilly paid up to $202 million for Engage Biologics, a seed-stage startup with no clinical trials and no named drug. The prize: a preclinical "Tethosome" platform that could crack the biggest problem in genetic medicine, getting DNA where it actually needs to go.
A Shanghai biotech just got the green light for the first-ever randomized CAR-T trial in liver cancer. The early data: a 50% response rate in patients who had run out of options. If it works, it could crack open the solid tumor door that CAR-T has been banging on for a decade.
Everyone building obesity drugs wants to activate the GIP receptor. Antag Therapeutics just showed up at ADA 2026 with human data proving the opposite approach is safe. Their contrarian bet could reshape how we treat the patients that current blockbusters leave behind.
Incyte just dropped $2 billion on a single Phase 3 drug for a bleeding disorder most people have never heard of. With Jakafi's patents expiring in 2028 and 70% of revenue on the line, this is either the smartest move in mid-cap pharma or the most expensive panic buy of the year.
Pfizer showed up to ADA 2026 with a once-monthly obesity shot that delivered 12.3% placebo-adjusted weight loss in Phase 2b. Wall Street called it "good, but not category-defining" — but in a market headed toward $100 billion, Pfizer's betting that convenience and tolerability matter more than being best-in-class.
Sarepta's flagship gene therapy just earned the FDA's most severe safety label after patient deaths, while the company simultaneously axed 500 jobs and pivoted its entire strategy. Wall Street somehow cheered. Here's why the story is more complicated than the stock price suggests.
Novo Nordisk's next-gen obesity shot CagriSema just lost a head-to-head Phase 3 trial against Eli Lilly's Zepbound, and Wall Street's reaction was savage. The result reshapes the competitive hierarchy in the world's hottest drug market.
GSK quietly acquired Elsie Biotechnologies for up to $50 million, but this tiny San Diego startup's real value isn't a drug — it's the machine that builds them. The deal reveals big pharma's escalating arms race for oligonucleotide platform technology.
Abivax's obefazimod posted the best maintenance remission numbers ever seen in an ulcerative colitis trial, with about 51% of patients staying in remission at 44 weeks. But a cluster of cancer cases in the high-dose arm sent the stock plunging 30–40% and now threatens to complicate the drug's entire regulatory future.
Roche and Zealand's petrelintide posted a near-placebo tolerability profile in Phase 2, with just 1.5% of patients quitting over GI side effects. In an obesity market where half of GLP-1 patients drop out within a year, that could be a bigger deal than the weight loss numbers suggest.
The FDA's new draft guidance lets gene therapy developers reuse manufacturing, safety, and clinical data across programs instead of starting from scratch every time. For an industry where approval takes 6–12 years, this could be a game-changer.
Eli Lilly just capped every Zepbound dose at $499/month through its direct-to-patient platform, slashing the top dose by over 50%. With compounding pharmacies shut down and Novo Nordisk undercutting on price, this move is less about generosity and more about locking down the obesity drug market.
Eli Lilly's triple-agonist retatrutide just posted 28% average weight loss in a Phase 3 trial, blowing past every GLP-1 drug on the market. The post-Ozempic era officially has a frontrunner.
The UK just committed at least £250 million to a new life sciences R&D site, its boldest infrastructure bet yet. But with Merck pulling a £1 billion expansion and the US outspending Europe nine-to-one on biotech, is it enough to stop the talent drain?
Join thousands of biotech professionals who start their day with our free, daily briefing.